Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Lilly's GLP-1 pill seen as superior in head-to-head trial with Novo's oral semaglutide
10:28am, Wednesday, 17'th Sep 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details about Eli Lilly's new drug trial.
GLP-1 drugs could save millions of lives — and spark a pension crisis
10:05am, Wednesday, 17'th Sep 2025
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study
09:03am, Wednesday, 17'th Sep 2025
Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with diabetes than oral semaglutide, the active ingredient in Danish rival Novo
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
09:00am, Wednesday, 17'th Sep 2025
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%)
Swiss Re says GLP-1 drugs could reduce US mortality by up to 6.4%
05:27am, Wednesday, 17'th Sep 2025
Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up to 6.4% in the United States by 2045.
- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. - ASC30 tablet's higher eff
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study Orforglipron demonstrated significant improvements acro
I Own The Gas Pump With Up To 10% Yields
10:30am, Saturday, 13'th Sep 2025
Pump fuel – get paid by these generous opportunities. Fuel distribution is essential for our economy, but often overlooked. All three opportunities covered issue a K-1 at tax time.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
06:30am, Saturday, 13'th Sep 2025
The oral GLP-1 segment is entering a pivotal stage, with major growth anticipated from 2026 onward. Patient preference for oral pills over injectables is strong, making ease of use a key driver for fu
Novo Nordisk: GLP-1's Concerns Are Overblown
04:41am, Saturday, 13'th Sep 2025
Novo continues to face U.S. market share pressure from Eli Lilly's Tirzepatide based GLP-1 and off-label semaglutide, but retains strong international GLP-1 dominance with 71% market share outside the
GLP-1 obesity pills face off in head-to-head trial
12:39pm, Friday, 12'th Sep 2025
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
The complaint alleges Novo overstated GLP-1 growth prospects; stock dropped 21.83% after lowered sales outlook citing compounded GLP-1 use and competition.
- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study. - 75-day ob
New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions
09:00am, Monday, 08'th Sep 2025
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada membe
Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs
07:30am, Monday, 08'th Sep 2025
Eli Lilly continues to do what it does best, which is to capture the obesity and type 2 diabetes treatment markets at an extremely rapid pace. So, sales of its flagship franchise called tirzepatide re
